ResearchMoz

Global Markets Direct Market Research Reports

Global Markets Direct is a leading provider of global business intelligence and market analysis. The company publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. With a large dedicated research and analysis capability, Global Markets Direct employs rigorous primary and secondary research techniques in developing unique data sets and research materials.

At the heart of Global Markets Direct are unique databases, updated live, covering millions of rows of key information for the studied industry at a global level.

List of reports from Global Markets Direct

Displaying 1 to 30 (of 2333 records)
Pages: « Last  1 2 3 4 5 6 7 8 9 10   Next »
Gram-Positive Bacterial Infections - Pipeline Review, H1 2013
Apr 2013  
Gram-Positive Bacterial Infections - Pipeline Review, H1 2013 Summary Global Markets Directs, 'Gram-Positive Bacterial Infections - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Gram-Positive Bacterial Infections, complete with latest updates, and special features on late-stage and...
$2000
Cutaneous T-Cell Lymphoma - Pipeline Review, H1 2013
Apr 2013  
Cutaneous T-Cell Lymphoma - Pipeline Review, H1 2013 Summary Global Markets Directs, 'Cutaneous T-Cell Lymphoma - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Cutaneous T-Cell Lymphoma, complete with latest updates, and special features on late-stage and discontinued projects. It...
$2000
Burns - Pipeline Review, H1 2013
Apr 2013  
Burns - Pipeline Review, H1 2013 Summary Global Markets Directs, 'Burns - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Burns, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic...
$2000
Indolent Lymphoma - Pipeline Review, H1 2013
Apr 2013  
Indolent Lymphoma - Pipeline Review, H1 2013 Summary Global Markets Directs, 'Indolent Lymphoma - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Indolent Lymphoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players...
$2000
Myelofibrosis - Pipeline Review, H1 2013
Apr 2013  
Myelofibrosis - Pipeline Review, H1 2013 Summary Global Markets Directs, 'Myelofibrosis - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Myelofibrosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in...
$2000
Osteosarcoma - Pipeline Review, H1 2013
Apr 2013  
Osteosarcoma - Pipeline Review, H1 2013 Summary Global Markets Directs, 'Osteosarcoma - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Osteosarcoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the...
$2000
Psychiatric Disorders - Pipeline Review, H1 2013
Apr 2013  
Psychiatric Disorders - Pipeline Review, H1 2013 Summary Global Markets Directs, 'Psychiatric Disorders - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Psychiatric Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews...
$2500
Waldenstrom Macroglobulinemia - Pipeline Review, H1 2013
Apr 2013  
Waldenstrom Macroglobulinemia - Pipeline Review, H1 2013 Summary Global Markets Directs, 'Waldenstrom Macroglobulinemia - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Waldenstrom Macroglobulinemia, complete with latest updates, and special features on late-stage and discontinued...
$2000
Post Menopausal Osteoporosis - Pipeline Review, H1 2013
Apr 2013  
Post Menopausal Osteoporosis - Pipeline Review, H1 2013 Summary Global Markets Directs, 'Post Menopausal Osteoporosis - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Post Menopausal Osteoporosis, complete with latest updates, and special features on late-stage and discontinued...
$2000
Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H1 2013
Apr 2013  
Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H1 2013 Summary Global Markets Directs, 'Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Post-Traumatic Stress Disorder (PTSD), complete with latest updates, and special features on...
$2000
Septic Shock - Pipeline Review, H1 2013
Apr 2013  
Septic Shock - Pipeline Review, H1 2013 Summary Global Markets Directs, 'Septic Shock - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Septic Shock, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the...
$2000
Streptococcal Infections - Pipeline Review, H1 2013
Apr 2013  
Streptococcal Infections - Pipeline Review, H1 2013 Summary Global Markets Directs, 'Streptococcal Infections - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Streptococcal Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also...
$2000
Ischemic Stroke - Pipeline Review, H1 2013
Apr 2013  
Ischemic Stroke - Pipeline Review, H1 2013 Summary Global Markets Directs, 'Ischemic Stroke - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Ischemic Stroke, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players...
$2000
Choroidal Neovascularization - Pipeline Review, H1 2013
Apr 2013  
Choroidal Neovascularization - Pipeline Review, H1 2013 Summary Global Markets Directs, 'Choroidal Neovascularization - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Choroidal Neovascularization, complete with latest updates, and special features on late-stage and discontinued...
$2000
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline Review, H1 2013
Apr 2013  
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline Review, H1 2013 Summary Global Markets Directs, 'Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Idiopathic Thrombocytopenic Purpura...
$2000
Diphtheria - Pipeline Review, H1 2013
Apr 2013  
Diphtheria - Pipeline Review, H1 2013 Summary Global Markets Directs, 'Diphtheria - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Diphtheria, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the...
$2000
Metastatic Lung Cancer - Pipeline Review, H1 2013
Apr 2013  
Metastatic Lung Cancer - Pipeline Review, H1 2013 Summary Global Markets Directs, 'Metastatic Lung Cancer - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Metastatic Lung Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also...
$2000
Uterine Cancer - Pipeline Review, H1 2013
Apr 2013  
Uterine Cancer - Pipeline Review, H1 2013 Summary Global Markets Directs, 'Uterine Cancer - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Uterine Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved...
$2000
Rabies - Pipeline Review, H1 2013
Apr 2013  
Rabies - Pipeline Review, H1 2013 Summary Global Markets Directs, 'Rabies - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Rabies, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic...
$2000
Chronic Plaque Psoriasis - Pipeline Review, H1 2013
Apr 2013  
Chronic Plaque Psoriasis - Pipeline Review, H1 2013 Summary Global Markets Directs, 'Chronic Plaque Psoriasis - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Chronic Plaque Psoriasis, complete with latest updates, and special features on late-stage and discontinued projects. It also...
$2000
Neuroendocrine Tumors - Pipeline Review, H1 2013
Apr 2013  
Neuroendocrine Tumors - Pipeline Review, H1 2013 Summary Global Markets Directs, 'Neuroendocrine Tumors - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Neuroendocrine Tumors, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews...
$2000
Partial Seizure - Pipeline Review, H1 2013
Apr 2013  
Partial Seizure - Pipeline Review, H1 2013 Summary Global Markets Directs, 'Partial Seizure - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Partial Seizure, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players...
$2000
Sarcopenia - Pipeline Review, H1 2013
Apr 2013  
Sarcopenia - Pipeline Review, H1 2013 Summary Global Markets Directs, 'Sarcopenia - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Sarcopenia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the...
$2000
Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline Review, H1 2013
Apr 2013  
Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline Review, H1 2013 Summary Global Markets Directs, 'Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Interstitial Cystitis (Painful Bladder Syndrome), complete with latest...
$2000
Pruritus - Pipeline Review, H1 2013
Apr 2013  
Pruritus - Pipeline Review, H1 2013 Summary Global Markets Directs, 'Pruritus - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Pruritus, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic...
$2000
B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H1 2013
Apr 2013  
B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H1 2013 Summary Global Markets Directs, 'B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for B-Cell Chronic Lymphocytic Leukemia, complete with latest updates, and special features on late-stage...
$2000
Bronchopulmonary Dysplasia - Pipeline Review, H1 2013
Apr 2013  
Bronchopulmonary Dysplasia - Pipeline Review, H1 2013 Summary Global Markets Directs, 'Bronchopulmonary Dysplasia - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Bronchopulmonary Dysplasia, complete with latest updates, and special features on late-stage and discontinued projects....
$2000
Friedreich Ataxia - Pipeline Review, H1 2013
Apr 2013  
Friedreich Ataxia - Pipeline Review, H1 2013 Summary Global Markets Directs, 'Friedreich Ataxia - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Friedreich Ataxia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players...
$2000
Secondary Hyperparathyroidism - Pipeline Review, H1 2013
Apr 2013  
Secondary Hyperparathyroidism - Pipeline Review, H1 2013 Summary Global Markets Directs, 'Secondary Hyperparathyroidism - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Secondary Hyperparathyroidism, complete with latest updates, and special features on late-stage and discontinued...
$2000
Burkitt Lymphoma - Pipeline Review, H1 2013
Apr 2013  
Burkitt Lymphoma - Pipeline Review, H1 2013 Summary Global Markets Directs, 'Burkitt Lymphoma - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Burkitt Lymphoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players...
$2000
 
Displaying 1 to 30 (of 2333 records)
Pages: « Last  1 2 3 4 5 6 7 8 9 10   Next »